NDAINTRAVENOUSPOWDERPriority Review
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FETROJA (cefiderocol sulfate tosylate) is an intravenous siderophore cephalosporin antibiotic that binds iron to penetrate gram-negative bacterial cell walls, approved for complicated urinary tract infections (cUTIs) and hospital/ventilator-associated bacterial pneumonia (HABP/VABP). It targets multidrug-resistant gram-negative organisms including Pseudomonas aeruginosa and Acinetobacter baumannii complex through a time-dependent pharmacodynamic mechanism where efficacy correlates with the percentage of time plasma concentrations exceed the organism's minimum inhibitory concentration.
$4.0MPart D
Peak9.3 years to LOEProduct is at peak lifecycle with modest Medicare spending ($4M in 2023, ~1,053 claims), indicating a specialized niche position in hospital infectious disease treatment with small but focused commercial team requirements.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FETROJA is a specialized infectious disease product with modest but stable commercial footprint ($4M Part D spending, 1,053 claims in 2023). Career opportunities align with niche hospital-based markets, microbiology expertise, and infectious disease specialist engagement rather than primary care or broad commercial scale.
Company
Worked on FETROJA at Shionogi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.